What is estetrol, and how is it different from other estrogens?

Estetrol is a native human estrogen normally made only by the fetal liver during pregnancy; adults don't otherwise produce it.

It has been developed as a pharmaceutical, manufactured from plant-derived starting material. It has an unusual receptor profile that activates one estrogen-receptor signaling pathway while leaving another largely alone in certain tissues, which is the proposed reason for its smaller effects on breast tissue and the liver, though that explanation is a reasoned extrapolation from receptor biology, not a proven clinical outcome. In actual trials, estetrol reduced weekly hot flush frequency significantly more than placebo, and a 12-week hemostasis study found its effect on clotting-related measures stayed within normal baseline ranges. It was approved in the European Union as menopausal hormone therapy in March 2026, based on a phase 3 program of over 2,500 women. There is no long-term outcome data yet on breast cancer, heart disease, fracture, or dementia for estetrol in any population, and because it doesn't normally circulate in adult life at all, there's no natural adult-exposure baseline to reason from the way there is for estradiol.

What to know about this answer

Estetrol's receptor pharmacology gives a genuine, non-marketing reason to think it might behave differently in the breast and liver than other estrogens, but that reasoning has not yet been tested against long-term clinical outcomes, and being native to human biology doesn't apply to estetrol the way it does to estradiol, since adults never naturally circulate it.

What the research shows, and which source each finding rests on

In a dose-finding trial of 257 postmenopausal women, 15 mg was the minimum effective daily dose of estetrol; weekly hot flush frequency fell 82% versus 65% for placebo at week 12

B [1]

In a phase 3 trial of 640 women aged 40-65, both 15 mg and 20 mg estetrol significantly reduced weekly hot flush frequency and severity versus placebo by week 12

B [2]

In a 12-week trial across four estetrol doses, thrombin generation parameters, a laboratory measure related to clotting, stayed within baseline reference ranges, described by the authors as a neutral profile on hemostasis; this is a surrogate laboratory endpoint, not a measure of actual clot events in women, and the study's authors were industry-affiliated

B [3]

The European Commission approved estetrol tablets (14.2 mg and 18.9 mg) as hormone replacement therapy for postmenopausal estrogen deficiency symptoms in March 2026, based on a phase 3 program of 2,576 women

E [4]

Where the real disagreement is

Each position is shown with its own sources. A position listed here is not necessarily the accepted view.

Estetrol's distinctive receptor profile is a genuinely promising, evidence-based reason for interest, not just a new brand

The researchers behind its development

Estetrol activates the nuclear estrogen receptor while leaving a separate membrane-based signaling pathway largely alone in specific tissues, a real, studied pharmacological distinction, and it is the proposed mechanism behind estetrol's comparatively small measured effects on breast tissue proliferation and liver parameters in early studies.

B [3]

The safety story is still an extrapolation, not a proven outcome

The honest limits named directly in the research

No long-term outcome data exist for estetrol in any population, breast cancer incidence, cardiovascular events, fracture, and dementia have simply not been studied; the favorable breast and clotting signals so far come from receptor pharmacology and short-term surrogate markers, not from outcome trials. And because estetrol is not part of normal adult physiology at all, circulating only during fetal life, the usual we're-just-replacing-what-the-body-makes argument doesn't apply to it the way it does for estradiol; nobody has studied what decades of adult exposure to a fetal-only estrogen does.

B [1]B [2]

What would settle it: Long-term outcome trials with breast cancer, cardiovascular, fracture, and cognitive endpoints, and a head-to-head trial against estradiol; neither exists yet.

What is really going on here

Is a safety claim about estetrol based on an actual outcome trial, or on receptor pharmacology and short-term surrogate lab measures?
Since estetrol doesn't naturally circulate in adult humans, does the usual this-just-replaces-what-your-body-makes reasoning actually apply to it?
Is estetrol currently approved and available where I am, or only in specific regions?

Questions for your doctor

Is estetrol an appropriate and available option for me, and how does it compare to estradiol for my specific symptoms and risk profile?
What is actually known, versus still unknown, about estetrol's long-term safety?
If I'm considering estetrol, what monitoring would we do given the absence of long-term outcome data?
Are there reasons related to my personal risk factors, like clotting or breast cancer history, that would make estetrol more or less suitable than estradiol for me?

Questions with no answer yet

Does estetrol's distinctive receptor profile actually translate into a lower long-term breast cancer or cardiovascular risk than estradiol, or does that remain a plausible mechanism that has never been tested against a hard clinical outcome?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: No long-term outcome data exist for estetrol in any population; breast cancer incidence, cardiovascular events, fracture, and dementia have simply not been studied. The favorable breast and clotting signals so far come from receptor pharmacology and short-term surrogate markers, not from outcome trials.

What would test it: Long-term outcome trials with breast cancer, cardiovascular, fracture, and cognitive endpoints, and a head-to-head trial against estradiol; neither exists yet.

Since estetrol does not normally circulate in adult human physiology at all, does decades of adult exposure to it behave the way a lifetime of exposure to estradiol does, or is the usual we-are-just-replacing-what-the-body-makes reasoning simply inapplicable to this particular molecule?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: Estetrol is produced only by the fetal liver during pregnancy and is effectively absent from adult physiology; because it has no natural adult exposure to reason from, this weakens the usual replacement argument used for other bioidentical hormones, and nobody has studied what decades of adult exposure to a fetal estrogen does.

What would test it: Long-term surveillance of women using estetrol as it becomes more widely available, alongside the outcome trials named above.

Sources

1.A multicenter, randomized study to select the minimum effective dose of estetrol (E4) in postmenopausal women (E4Relief): part 1. Vasomotor symptoms and overall safety.Gaspard U, et al. A multicenter, randomized study to select the minimum effective dose of estetrol (E4) in postmenopausal women (E4Relief): part 1. Menopause 2020;27(8):848-857. · Randomised trial
2.Estetrol (E4) for the treatment of moderate to severe vasomotor symptoms in postmenopausal women - Efficacy and safety results from the phase 3 E4COMFORT I multicenter, placebo-controlled study.Simoncini T, et al. Estetrol (E4) for the treatment of moderate to severe vasomotor symptoms in postmenopausal women: efficacy and safety results from the phase 3 E4COMFORT I study. Maturitas 2026;209:108965. · Randomised trial
3.Low thrombin generation in postmenopausal women using estetrol.Morimont L, et al. Low thrombin generation in postmenopausal women using estetrol. Climacteric 2024;27(2):193-201. · Randomised trial
4.Gedeon Richter. European Commission approval of estetrol tablet as hormone replacement therapy for postmenopausal women, March 2026.Review, opinion or mechanism

The letter grades the type of study behind a claim, not the answer itself.

This page is general information based on published research and public sources. It is not medical advice and not a personal assessment, and it does not replace a conversation with your doctor. Peritale is a wellness product, not a medical device, and is not intended to diagnose, treat, cure or prevent any disease. For any medical question, speak with a licensed clinician.

You are not imagining it

In about seven minutes on your phone, Peritale reads five signal systems and maps your symptoms, so you can see that what you feel is real, follow your hormonal transition over time, and walk into your doctor ready to ask for the care you deserve. Your first check is free, no credit card.

Start Free Mapping